[
  {
    "ts": null,
    "headline": "Biogen Inc. stock underperforms Wednesday when compared to competitors",
    "summary": "Biogen Inc. stock underperforms Wednesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=1870571ddbc25b611abc1afc4491407d5059fe09523aee5510bb0af602009606",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758733620,
      "headline": "Biogen Inc. stock underperforms Wednesday when compared to competitors",
      "id": 136879032,
      "image": "",
      "related": "BIIB",
      "source": "MarketWatch",
      "summary": "Biogen Inc. stock underperforms Wednesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=1870571ddbc25b611abc1afc4491407d5059fe09523aee5510bb0af602009606"
    }
  },
  {
    "ts": null,
    "headline": "Biogen’s high-dose Spinraza turned down by FDA due to CMC troubles",
    "summary": "Biogen is one in a list of companies that have recently faced rejections due to CMC issues.",
    "url": "https://finnhub.io/api/news?id=da12d0982551b9236a238bc5245ec4871661f251c6e6150f2708121a8096ddea",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758732587,
      "headline": "Biogen’s high-dose Spinraza turned down by FDA due to CMC troubles",
      "id": 136866401,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen is one in a list of companies that have recently faced rejections due to CMC issues.",
      "url": "https://finnhub.io/api/news?id=da12d0982551b9236a238bc5245ec4871661f251c6e6150f2708121a8096ddea"
    }
  },
  {
    "ts": null,
    "headline": "BIIB's sNDA for Higher Dose of SMA Drug Spinraza Gets FDA's CRL",
    "summary": "FDA issues CRL to Biogen's regulatory filing seeking approval for a higher dose of SMA drug, Spinraza. The company plans prompt resubmission.",
    "url": "https://finnhub.io/api/news?id=7c0564f30358a62b2bcf5d24b586d952a7f0cc23b3cf038062f7b4e0201d2408",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758732060,
      "headline": "BIIB's sNDA for Higher Dose of SMA Drug Spinraza Gets FDA's CRL",
      "id": 136866402,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "FDA issues CRL to Biogen's regulatory filing seeking approval for a higher dose of SMA drug, Spinraza. The company plans prompt resubmission.",
      "url": "https://finnhub.io/api/news?id=7c0564f30358a62b2bcf5d24b586d952a7f0cc23b3cf038062f7b4e0201d2408"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Inc. (BIIB) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript",
    "summary": "Biogen Inc. (NASDAQ:BIIB) Bernstein 2nd Annual Global Healthcare Conference September 24, 2025 11:20 AM EDTCompany ParticipantsPriya Singhal - Executive VP...",
    "url": "https://finnhub.io/api/news?id=3078282ea5b401501741f4de9956d2a7a260fc35bfa609d0a7a772edbb5f908f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758723462,
      "headline": "Biogen Inc. (BIIB) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript",
      "id": 136863971,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "BIIB",
      "source": "SeekingAlpha",
      "summary": "Biogen Inc. (NASDAQ:BIIB) Bernstein 2nd Annual Global Healthcare Conference September 24, 2025 11:20 AM EDTCompany ParticipantsPriya Singhal - Executive VP...",
      "url": "https://finnhub.io/api/news?id=3078282ea5b401501741f4de9956d2a7a260fc35bfa609d0a7a772edbb5f908f"
    }
  },
  {
    "ts": null,
    "headline": "LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia",
    "summary": "TOKYO and CAMBRIDGE, Mass., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the Therapeutic Goods Administration (TGA) of Australia has approved the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” (brand name, generic name: lecanemab) for mild cognitive impairment (MCI",
    "url": "https://finnhub.io/api/news?id=46ece89daf0b59f071cae449c3615e2d4098fd18f77ea37863861a6eac44d33e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758713400,
      "headline": "LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia",
      "id": 136862169,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "TOKYO and CAMBRIDGE, Mass., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the Therapeutic Goods Administration (TGA) of Australia has approved the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” (brand name, generic name: lecanemab) for mild cognitive impairment (MCI",
      "url": "https://finnhub.io/api/news?id=46ece89daf0b59f071cae449c3615e2d4098fd18f77ea37863861a6eac44d33e"
    }
  }
]